Literature DB >> 3038646

Proliferation of a human epidermal tumor cell line stimulated by urokinase.

J C Kirchheimer, J Wojta, G Christ, B R Binder.   

Abstract

Several tumor cells secrete significantly increased amounts of the plasminogen activator urokinase, a trypsinlike serine protease, whose biological function in tumor biology is unclear. In this study we report that cells of the human epidermal tumor cell line CCL 20.2 express about 80,000 high-affinity urokinase receptors per cell that bind active as well as diisopropylfluorophosphate-treated high-molecular-weight (HMW) urokinase. Low-molecular-weight (LMW) urokinase is not bound to the receptor. Occupation of these receptors by active HMW urokinase stimulates cell proliferation independently in the presence of plasminogen in the culture medium. LMW urokinase has again no effect on cell proliferation. Calculated on a molar basis, this effect is about 28% of that of epidermal growth factor. Active HMW urokinase might therefore provide an autocrine receptor-mediated growth-promoting mechanism for tumor cells similar to those described for other growth factors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038646     DOI: 10.1096/fasebj.1.2.3038646

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  22 in total

1.  D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.

Authors:  Gabriele Eden; Marco Archinti; Ralitsa Arnaudova; Giuseppina Andreotti; Andrea Motta; Federico Furlan; Valentina Citro; Maria Vittoria Cubellis; Bernard Degryse
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

Review 2.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

3.  Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.

Authors:  Fang Wang; Jing Li; Anthony L Sinn; W Eric Knabe; May Khanna; Inha Jo; Jayne M Silver; Kyungsoo Oh; Liwei Li; George E Sandusky; George W Sledge; Harikrishna Nakshatri; David R Jones; Karen E Pollok; Samy O Meroueh
Journal:  J Med Chem       Date:  2011-10-04       Impact factor: 7.446

4.  Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.

Authors:  J C Kirchheimer; J Wojta; G Christ; B R Binder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.

Authors:  U Reuning; O Wilhelm; T Nishiguchi; L Guerrini; F Blasi; H Graeff; M Schmitt
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

Review 6.  Spinal cord compression in prostate cancer.

Authors:  J L Osborn; R H Getzenberg; D L Trump
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.

Authors:  A R Nusrat; H A Chapman
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

8.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 9.  Plasminogen activator inhibitor-1: the double-edged sword in apoptosis.

Authors:  Rashna D Balsara; Victoria A Ploplis
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

Review 10.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.